PUBLISHER: Grand View Research | PRODUCT CODE: 1301116
PUBLISHER: Grand View Research | PRODUCT CODE: 1301116
The global neglected tropical diseases diagnosis market size is expected to reach USD 8.97 billion by 2030, expanding at a CAGR of 4.5% during the forecast period, according to a new report by Grand View Research, Inc. Increasing disease burden, growing demand for early disease identification, and complementary advancements in technology is expected to drive growth in demand.
Increasing concern regarding neglected tropical diseases and their impact on the population as well as economies has boosted the demand for the development of early disease detection methods. This growth in concern is evident in the launch of a substantial number of programs aiming to combat NTDs. For instance, the Global Network for Neglected Tropical Diseases aims to raise awareness and funding, both of which are essential to control and eliminate the most common NTDs. In addition, various companies are undertaking efforts to develop less complicated and inexpensive diagnostic assays for tropical diseases. In January 2021, Novartis AG signed an agreement with the WHO to manage leprosy across the globe. This, in turn, is anticipated to support the growth of this market throughout the forecast period.
According to the WHO, as of January 2022, more than 1.5 billion people are infected with soil-transmitted helminth infections worldwide. The Kato-Katz technique is the WHO gold standard that is widely used to diagnose the intensity of STHs. These infections are distributed widely in tropical and subtropical areas majorly occurring in America, sub-Saharan Africa, East Asia, and China. Furthermore, the presence of key players is expected to fuel the overall market growth. The involvement of these players in new product development is considered to be the contributing factor to the development of the NTD diagnosis market.